KRAS wild-type cancers had lower GALNT6 mRNA expression levels than KRAS mutated cancers, whereas BRAF mutated tumors had lower GALNT6 mRNA expression levels than BRAF wild-type tumors. This evidence concerns the gene GALNT6 and cancer.